< Back to previous page
Researcher
Pieter Annaert
- Disciplines:Biomarker discovery and evaluation, Drug discovery and development, Medicinal products, Pharmaceutics, Pharmacognosy and phytochemistry, Pharmacology, Pharmacotherapy, Toxicology and toxinology, Other pharmaceutical sciences
Affiliations
- Department of Pharmaceutical and Pharmacological Sciences (Department)
Responsible
From15 Feb 2025 → Today - Drug Delivery and Disposition (Division)
Member
From1 Oct 2005 → Today
Projects
1 - 10 of 37
- Repurposing paracetamol to improve neonatal asphyxia (REPAIR-Neo)From25 Sep 2025 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Repurposing Paracetamol to ImpRove NEOnatal asphyxia (REPAIR-NEO study)From1 Oct 2024 → TodayFunding: BOF - projects
- Sabbatical Pieter Annaert: Metabolomics meets Quantitative Systems Pharmacology&ToxicologyFrom15 Sep 2024 → 14 Feb 2025Funding: FWO Prices and sabbaticals (before FWO undefined), BOF - mobility
- Investigating current gaps in time-dependent inhibition (TDI) and induction drug-drug interactions (DDIs). A focus on CYPs and non-CYPs drug metabolizing enzymes (DMEs).From24 May 2023 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Improved clearance prediction using ex vivo and new in silico tools to bridge the in vitro to in vivo extrapolation (IVIVE) gapFrom1 Oct 2022 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Investigation of bidirectional pharmacokinetic drug-drug interaction between vicagrel, a novel analogue for the antiplatelet drug clopidogrel, and atorvastatinFrom15 Sep 2022 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Design and development of FabV inhibitors as a new class of antibacterials for pathogenic Gram-negative bacteriaFrom1 Oct 2021 → TodayFunding: Baekeland
- Gaining Mechanistic Understanding of Drug-Induced Cholestasis by Modeling and Simulation ApproachesFrom1 Oct 2021 → 15 Sep 2025Funding: Own budget, for example: patrimony, inscription fees, gifts
- Physiologically-based pharmacokinetic modelling and simulation to optimize exposure to medicines in perinatal populationsFrom1 Oct 2021 → 1 Oct 2025Funding: Own budget, for example: patrimony, inscription fees, gifts
- Physiologically-based pharmacokinetic modelling across special populations: Insights into older adults and obesityFrom1 Oct 2021 → 17 Oct 2025Funding: Own budget, for example: patrimony, inscription fees, gifts
Publications
1 - 10 of 276
- Systematic Search of Height and Weight Changes of Exclusively Breastfed Infants Until 1 Year of age: A Contribution from the ConcePTION Project(2025)Published in: Clinical PharmacokineticsISSN: 0312-5963Issue: 11Volume: 64Pages: 1599 - 1619
- Kennis kent geen einde. De beweging van de universiteit(2025)Number of pages: 152
- Physiologically-based pharmacokinetic modelling across special populations: Insights into older adults and obesity(2025)
- Clinical and preclinical evaluation of the treatment of hepatocellular carcinoma: focus on pharmacokinetics(2025)
- Electronic Patient File-Embedded Model-Informed Precision Dosing Compared with Physician Dosing of Tacrolimus in Kidney Transplantation(2025)Published in: CLINICAL PHARMACOLOGY & THERAPEUTICSISSN: 0009-9236
- Infant exposure to maternal medicines via human milk: compiling infant population physiology and developing a clinical lactation trial workflow(2025)
- Predicting Systemic and Liver Bosentan Exposure Using Physiologically-Based Pharmacokinetic Modeling(2025)Published in: CPT: Pharmacometrics & Systems PharmacologyISSN: 2163-8306Issue: 10Volume: 14Pages: 1715 - 1726
- Physiologically-based pharmacokinetic modelling and simulation to optimize exposure to medicines in perinatal populations(2025)
- Progression of the estimated glomerular filtration rate in asphyxiated neonates undergoing therapeutic hypothermia during the first 10 days of life(2025)Published in: PEDIATRIC NEPHROLOGYISSN: 0931-041X
- Quantitative UHPLC-MS/MS Analysis of Gemcitabine and Its Active and Inactive Metabolites in Pig Plasma and Lung Tissue in Preparation of Locoregional Therapies for Non-Small Cell Lung Cancer(2025)Published in: Journal of Mass SpectrometryISSN: 1076-5174Issue: 10Volume: 60
Linked dataset
1 - 2 of 2
- Bidirectional permeability of model medicines in an in vitro model based on primary culture of human (hMECs) or Göttingen minipig (mpMECs) mammary epithelial cells.
- Characterization of in vitro model based on primary culture of human mammary epithelial cells (hMECs): barrier integrity and functionality of transport routes.